These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20103549)

  • 61. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians.
    Nelson CR; Knapp DA
    Hypertension; 2000 Oct; 36(4):600-3. PubMed ID: 11040242
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
    Norris SL; Carson S; Roberts C
    Curr Diabetes Rev; 2007 May; 3(2):127-40. PubMed ID: 18220664
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
    Vaduganathan M; Patel RB; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2019 Apr; 73(12):1596-1598. PubMed ID: 30922481
    [No Abstract]   [Full Text] [Related]  

  • 64. [One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].
    Slama G; Eschwège E; Bernard MH; Grimaldi A; Oppert JM; Pouchain D; Bégaud B;
    Ann Endocrinol (Paris); 2008 Feb; 69(1):36-46. PubMed ID: 18243155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
    Erdmann E; Scherbaum WA
    MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
    [No Abstract]   [Full Text] [Related]  

  • 68. Diabetic macular edema associated with glitazone use.
    Ryan EH; Han DP; Ramsay RC; Cantrill HL; Bennett SR; Dev S; Williams DF
    Retina; 2006; 26(5):562-70. PubMed ID: 16770264
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thiazolidinediones: a comparative review of approved uses.
    Sood V; Colleran K; Burge MR
    Diabetes Technol Ther; 2000; 2(3):429-40. PubMed ID: 11467345
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug utilization, safety and clinical use of Actos and Avandia.
    Marks DH
    Int J Risk Saf Med; 2013 Jan; 25(1):39-51. PubMed ID: 23442297
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
    Habib ZA; Tzogias L; Havstad SL; Wells K; Divine G; Lanfear DE; Tang J; Krajenta R; Pladevall M; Williams LK
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):437-47. PubMed ID: 19235778
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pioglitazone is a valid alternative to rosiglitazone.
    Derosa G
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
    Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
    Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.
    Mehta SN; Goldfine AB; Abrahamson MJ; DiVincenzo R; Laffel LM
    J Diabetes Sci Technol; 2013 Jan; 7(1):119-22. PubMed ID: 23439167
    [TBL] [Abstract][Full Text] [Related]  

  • 75. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians.
    Mark TL
    CNS Drugs; 2010 Apr; 24(4):319-26. PubMed ID: 20297856
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
    Kemp-Casey A; Mintzes B; Morrow RL; Dormuth CR; Souverein PC; Roughead EE
    Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1039-1045. PubMed ID: 35790047
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Detecting Secular Trends in Clinical Treatment through Temporal Analysis.
    Redd D; Shao Y; Cheng Y; Zeng-Treitler Q
    J Med Syst; 2019 Feb; 43(3):74. PubMed ID: 30756197
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.
    Meléndez-Flores JD; Millán-Alanís JM; González-Martínez A; Álvarez-Villalobos NA; Estrada-Bellmann I
    Metab Brain Dis; 2020 Oct; 35(7):1067-1075. PubMed ID: 32363472
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ambulatory Fluoroquinolone Use in the United States, 2015-2019.
    Umarje SP; Alexander CG; Cohen AJ
    Open Forum Infect Dis; 2021 Dec; 8(12):ofab538. PubMed ID: 34901300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.